Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a dengue vaccine be both Cost-Effective and trusted? a thai study investigates

NCT ID NCT07759596

Knowledge-focused Sponsor: Mahidol University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This study has two parts. First, researchers will use computer models to estimate whether giving the TAK-003 dengue vaccine to Thai children aged 9-14 or young adults aged 15-24 would be good value for money for the national immunization program. Second, they will survey Thai adults and parents of children aged 4-18 to understand what influences their willingness to get the dengue vaccine, including beliefs, concerns, and cost. The goal is to provide evidence that could help Thailand decide how to roll out dengue vaccination effectively and build public trust.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TAK-003 dengue vaccine (evaluated for cost-effectiveness, not administered to participants)
What this could lead to
If successful, this could guide Thailand's decision on adding the dengue vaccine to its national immunization program, potentially reducing dengue burden in high-risk age groups.
What could go wrong
This is an economic and survey-based study, not a clinical efficacy trial. Results depend on model assumptions and survey responses, which may not reflect real-world vaccine uptake or long-term effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

General population Inclusion criteria - Visiting hospitals for routine follow up their medical conditions at Med OPD, Hospital for Tropical Diseases Mahidol University. Parents Inclusion criteria \- Visiting hospitals for their children's routine follow up appointment at children OPD Siriraj Hospital, Mahidol University

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General population Inclusion criteria * Both males and females Thai * Adults aged 18 years and older * Willing to participate in the study * Never received dengue vaccine * either single or married status without legitimate children * having independent sources of incomes. Exclusion criteria * All types of Health care personnel * visiting hospital due to clinical suspicions or confirmation of dengue infection * Have no prior knowledge or awareness of dengue or dengue vaccines. Parents Inclusion criteria * Both males and females Thai * Adults aged 18 years and older * Willing to participate in the study * Having legitimate children aged 4 to 18 years old with dengue vaccine naïve * Having independent sources of income. Exclusion criteria * All types of Health care personnel * Visiting hospital due to their children's illnesses such as clinical suspicions or confirmation of dengue infection. * Have no prior knowledge or awareness of dengue or dengue vaccines.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dengue fever are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Financial Stress dengue disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dengue fever

Contacts and locations

Locations

  • Hospital for Tropical Diseases, Faculty of Tropical Medicine

    Bangkok, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.